Bioprosthesis In Mitral Position Research Articles

Post operative echocardiographic follow up after mitral valve replacement by different types of biological valves

Abstract Objectives This retrospective study compares porcine with bovine bioprosthesis in mitral position with regard to valvular degeneration. Methods Between 2005 and 2019, 15 patients underwent mitral valve replacement with porcine Epic biological valve (St-Jude) and 15 patients underwent mitral valve replacement by bovine Carpentier –Edwards Perimount biological valve and follow up ecocardiogarphy was done to evaluate valvular degeneration of both types Results Bovine type showed longer durability than porcine and less valvular degeneration within 14 years of follow up regardless age of patient, cause of valve replacement, or lesion of valve Coclusion: Bovine bioprothesis are better than porcine regarding durability

The serendipity history of a bioprosthesis in mitral position: An incessant competition among manufacturers having no winner.

The authors declare no conflict of interests.

Immediate results of using a frame-mounted xeno-pericardial bioprosthesis in mitral position with an Easy Change System

Aim. To assess the immediate results of mitral valve prosthetics with the MedEng-BIO biological valve based on 19 clinical observations. Material and Methods. The implantation of the MedEng-BIO biological valve prosthesis to the mitral position was performed in 19 patients at the Cardiology Research Institute of Tomsk National Research Medical Center of the Russian Academy of Science (Tomsk, Russia) between February 2017 and January 2019. The average age of patients was 68.7 ± 5.4 years. The NYHA functional class was 2.61 ± 0.50. The average peak preoperative gradient was 18.3 ± 5.9 mmHg; the mean gradient was 7.1 ± 3.3 mmHg. All the patients underwent echocardiography to study the mitral valve, the left ventricular function, the left atrial (LA) size, and the right ventricular systolic pressure (RVSP) preoperatively and before the discharge (14 days after the surgery on average). Results. There were no statistically significant changes in the left ventricular function; the decreases in the LA sizes and the RVSP are shown in Table 2. The effective opening areas of the MedEng-BIO valves of the sizes 27, 29, and 31 were 3.2, 2.7, and 2.06 cm 2 , respectively. Conclusions. The first experience of using the MedEng-BIO biological mitral valve prostheses demonstrated satisfactory clinical outcomes with the simplification of the implantation procedure and a possible decrease in the risk of postoperative complications in repeated interventions. However, more cases and more extended observations are needed to draw final and statistically significant conclusions on the effect and feasibility of this surgical procedure.

Emergency transapical mitral valve-in-valve implantation for bioprosthesis failure: transapical implantation of an Edwards Sapien-XT in a dysfunctional mitral bioprosthesis in a critical patient

BackgroundValve-in-Valve (VIV) Transcatheter Aortic Valve Replacement (TAVR) is now the treatment of choice in high-surgical-risk patients with failing aortic bioprosthesis. Although less performed, VIV-Transcatheter Mitral Valve Replacement (TMVR) is a valid treatment option for selected high-risk patients with degenerated mitral bioprostheses. Several cases of elective ViV- TAVR and -TMVR have been reported but only few were performed in critical hemodynamic conditions.Case presentationWe report the case of a patient underwent balloon-expandable transapical mitral valve-in-valve implantation in an emergency setting due to a severe stenosis of a bioprosthesis in mitral position. The procedure was successfully performed, with no residual mitral regurgitation or paravalvular leaks, and uneventful.ConclusionTranscatheter transapical mitral valve-in-valve implantation could represent a feasible and effective strategy even in critical setting.

Transfemoral and Transseptal Valve-in-Valve Implantation Into a Failing Mitral Xenograft With a Balloon-Expandable Biological Valve

Valve-in-valve implantation for degenerated surgical bioprosthetic valves is becoming an increasingly accepted approach in selected high-risk patients. In the past, valve-in-valve implantations have been mainly performed in aortic position and only rarely in mitral position. We describe the case of an 81-year-old female patient with severe mitral regurgitation of a degenerated Carpentier-Edwards biological prosthesis treated by transfemoral and transseptal implantation of a SAPIEN-XT valve.

Unexpected long durability of a low-profile porcine Liotta bioprosthesis in mitral position

We report a case in which replacement of a low-profile porcine Liotta bioprosthesis was required 21 years after initial implantation. The patient underwent mitral valve replacement with a 28-mm Liotta bioprosthesis in 1985 for mitral stenosis. Twenty-one years later, severe mitral regurgitation was detected at echocardiography and mitral valve reoperation combined with tricuspid annuloplasty was successfully performed. Focal perforation of two cusps with consequent intravalvular leak on bioprosthesis was found. This is the longest durability report for a Liotta bioprosthesis in mitral position.